InsiderSignal.AI

InsiderSignal.ai

ARQT - Arcutis Biotherapeutics, Inc.

Insider Sale by Welgus Howard G. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Welgus Howard G., serving as Dir at Arcutis Biotherapeutics, Inc. (ARQT), sold 10,000 shares at $23.88 per share, for a total transaction value of $238,801.00. Following this transaction, Welgus Howard G. now holds 39,744 shares of ARQT.

This sale represents a 20.00% decrease in Welgus Howard G.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Arcutis Biotherapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Welgus Howard G.

Welgus Howard G.

Dir

Howard G. Welgus, MD, FAAD is a board-certified dermatologist and experienced pharmaceutical executive serving as a director of Arcutis Biotherapeutics Inc.[[1]](https://www.arcutis.com/leadership/howard-welgus/)[[4]](https://www.gurufocus.com/insider/130024/howard-g.-welgus) He earned his BA in biology from Rice University and completed his MD from Washington University School of Medicine in St. Louis, where he subsequently spent 17 years as faculty, achieving tenure as a full professor and publishing over 120 peer-reviewed articles.[[1]](https://www.arcutis.com/leadership/howard-welgus/) Dr. Welgus is a fellow of the American Academy of Dermatology and holds membership in several prestigious medical societies including the American Dermatologic Association and the American Society of Clinical Investigation.[[1]](https://www.arcutis.com/leadership/howard-welgus/) Throughout his career, Dr. Welgus has held significant leadership positions in the pharmaceutical industry. He joined Pfizer in 1999, serving as Vice President and head of dermatology and inflammation therapeutic areas for a decade, during which he contributed to the development of Lyrica® for fibromyalgia and Xeljanz® for rheumatoid arthritis and psoriatic arthritis.[[1]](https://www.arcutis.com/leadership/howard-welgus/) He subsequently served as chief medical officer and head of R&D at Nycomed for three years before joining Verrica Pharmaceuticals as chief medical officer.[[1]](https://www.arcutis.com/leadership/howard-welgus/) At Arcutis, Dr. Welgus served as chief medical officer from 2016 until his retirement in July 2020, when he transitioned to the board of directors.[[1]](https://www.arcutis.com/leadership/howard-welgus/)

View full insider profile →

Trade Price

$23.88

Quantity

10,000

Total Value

$238,801.00

Shares Owned

39,744

Trade Date

Wednesday, April 1, 2026

3 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Arcutis Biotherapeutics, Inc.

Company Overview

No company information available
View news mentioning ARQT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5335551

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime